HOME CONTROL INTERNATIONAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1747)

VOLUNTARY ANNOUNCEMENT ENTERING INTO A STRATEGIC COOPERATION MEMORANDUM AND EXPLORATION OF BUSINESS OPPORTUNITIES RELATING TO LOCALISED HEALTHCARE AI AND DIGITAL HEALTH IN INDONESIA

This announcement is made by Home Control International Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders of the Company (the "**Shareholders**") and potential investors of the latest business development of the Group.

STRATEGIC COOPERATION MEMORANDUM

The board (the "**Board**") of directors (the "**Directors**", and each a "**Director**") of the Company hereby announces that, on 23 July 2026, the Company, through its wholly-owned subsidiary, Orbiva Limited ("**Orbiva**"), entered into a strategic cooperation memorandum (the "**Memorandum**") with PT Articura Tech Indonesia ("**Articura**"). The Memorandum records the parties' preliminary intention to establish a strategic cooperation framework in relation to market opportunities concerning healthcare artificial intelligence ("**AI**") infrastructure and digital health solutions that comply with Indonesia's local data storage, data sovereignty and regulatory requirements (the "**Localised Healthcare AI**"). Except for those provisions of the Memorandum expressly stated to be legally binding, the specific cooperation arrangements contemplated under the Memorandum will only be implemented subject to further negotiations between the parties and the execution of definitive agreement(s).

Pursuant to the Memorandum, the parties intend to explore cooperation and conduct feasibility assessments in the following areas. The proposed scope of cooperation principally includes:

(i) **Exploration of Localised Healthcare AI Infrastructure and Digital Health Opportunities in Indonesia.** The parties intend to explore the establishment, adaptation and optimisation of healthcare AI reasoning-rule systems and intelligent engines that meet Indonesia's local healthcare needs, clinical practices, regulatory requirements and data sovereignty principles. These may encompass healthcare-specific reasoning rules, clinical logic, medical knowledge representation, AI-assisted decision-making and privacy-preserving AI architectures. The parties also intend to assess suitable foundation models, language intelligence for the healthcare domain and localised large language model capabilities. Such exploration does not constitute a commitment by either party to independently develop a foundation large language model, and any specific technical implementation, cooperation model or deployment plan will be subject to separate written agreement;

(ii) **Development of healthcare data and knowledge systems for local hospitals and clinics.** The parties intend to explore the cleansing, integration, standardisation and structured management of clinical data from hospitals and clinics across Indonesia, and to establish data processing methodologies, clinical knowledge systems and data governance mechanisms aligned with Indonesia's local disease profile, clinical pathways and healthcare needs, in order to support the continuous optimisation of the relevant healthcare AI reasoning-rule systems, intelligent engines and application capabilities;

(iii) **Home healthcare, remote monitoring and digital health records.** The parties intend to explore the integration of health-monitoring devices, digital health records and AI-driven health management capabilities to extend relevant healthcare services into the home. Subject to compliance with applicable laws and requirements relating to data protection and authorisation, such services may integrate multimodal health information from authorised medical devices and services, and facilitate data connectivity among hospitals, clinics and homes, in support of chronic disease management, preventive care and personalised healthcare services;

(iv) **Deployment of healthcare AI applications in hospital settings.** The parties intend to explore the deployment of localised AI infrastructure in hospital settings and its integration with the healthcare AI reasoning-rule systems and intelligent engines proposed to be jointly developed by the parties. Any such deployment will be designed having regard to local healthcare needs, clinical pathways, clinical case quality-control standards and applicable regulatory requirements in Indonesia, and may cover functions such as AI-enabled pre-consultation and patient triage, clinical decision support, improvement and quality control of medical records, AI-enabled patient follow-up, and optimisation of hospital operating efficiency; and

(v) **Market cooperation, regional expansion and long-term strategic alignment.** The parties intend to jointly engage with Indonesian government authorities, healthcare institutions and other healthcare industry stakeholders to explore digital healthcare projects and market cooperation opportunities that comply with local regulatory requirements. Articura intends to be responsible for communications and coordination with local stakeholders and for advancing market cooperation, while Orbiva intends to provide AI architecture, technical documentation and implementation support. Subject to further discussions between the parties, Indonesia may serve as a basis for the future expansion of relevant Localised Healthcare AI solutions into other ASEAN markets. In addition, the Memorandum contains arrangements relating to potential investment cooperation. Any specific investment, valuation, investment amount, regulatory approval and transaction documentation will be subject to separate negotiations among the relevant parties, the execution of definitive transaction documents, and the fulfilment of applicable approval and disclosure procedures.

The Memorandum principally sets out the parties' intentions and framework in respect of the proposed strategic cooperation. The provisions of the Memorandum relating to confidentiality, data protection and compliance, restrictions on publicity and disclosure, exclusivity, dispute resolution, governing law and certain general provisions are legally binding; save for the foregoing provisions, the other provisions of the Memorandum are not legally binding. The exclusivity arrangements apply solely to the specific strategic cooperation framework described in the Memorandum and do not restrict either party from independently engaging with third parties in other healthcare, AI, technology, investment or commercial activities. The specific cooperation arrangements contemplated under the Memorandum will only be implemented subject to further negotiations between the parties and the execution of definitive agreement(s).

INFORMATION ON THE PARTIES

Orbiva is a wholly-owned subsidiary of the Company. The Group is headquartered in Singapore, traces its origins to the home-control division of Koninklijke Philips N.V., and has built up longstanding experience and capabilities in smart devices, global supply chain management and related product commercialisation. Leveraging its capabilities in smart hardware commercialisation, supply chain integration and global market operations, Orbiva is committed to promoting innovation in, and the deployment of, smart devices and AI-related technologies across different applications.

Articura is an Indonesian healthcare AI technology company with local healthcare digitalisation capabilities and experience in deploying AI applications in healthcare. To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, Articura and its ultimate beneficial owner(s) are third parties independent of the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")).

REASONS FOR AND BENEFITS OF BUSINESS EXPLORATION AND ENTERING INTO THE MEMORANDUM

The Company intends, through its wholly-owned subsidiary Orbiva and under the cooperation framework set out in the Memorandum, to conduct preliminary exploration with Articura of cooperation opportunities in Indonesia relating to Localised Healthcare AI infrastructure and digital health solutions that comply with applicable local laws and regulations and requirements relating to data protection and data sovereignty. Such cooperation remains at a preliminary exploratory stage, and the specific scope of cooperation, implementation arrangements and commercial terms will only be determined subject to further negotiations between the parties and the execution of definitive agreement(s).

Shareholders and potential investors should note that this announcement is made by the Company on a voluntary basis for the purpose of keeping the public informed of the latest business development of the Group. The Board wishes to emphasise that the cooperation contemplated under the Memorandum remains at the exploration and assessment stage. As at the date of this announcement, the parties have not entered into any agreement with, or been awarded any project by, any Indonesian government authority in relation to such cooperation, and such cooperation has not received any recognition, support, approval, authorisation or endorsement from any Indonesian government authority. The relevant projects, transactions and/or commercial arrangements may or may not materialise. If any project and/or transaction contemplated under the Memorandum materialises and constitutes a matter required to be disclosed by the Company under the Listing Rules, the Company will make further announcement(s) as and when appropriate. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

On behalf of the Board of Directors
Home Control International Limited
Kwok Hoong SIU
Chief Executive Officer and Executive Director

Hong Kong, 27 July 2026

As at the date of this announcement, the Board comprises Mr. Kwok Hoong SIU and Mr. Haofang YANG as executive Directors; Ms. Ying MA as non-executive Director; and Mr. Min YE, Mr. Yi Chung CHEN and Mr. Bernard Eng Chuan LIM as independent non-executive Directors.